Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2016

  • ID: 3635641
  • Report
  • 100 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • aTyr Pharma, Inc.
  • Baxalta Incorporated
  • CSL Limited
  • GeNeuro SA
  • INSYS Therapeutics, Inc.
  • Neurocentrx Pharma Ltd.
  • MORE
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2016

Summary

The report ‘Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2016’, provides an overview of the Peripheral Neuropathy (Sensory Neuropathy) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peripheral Neuropathy (Sensory Neuropathy)
- The report reviews pipeline therapeutics for Peripheral Neuropathy (Sensory Neuropathy) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Peripheral Neuropathy (Sensory Neuropathy) therapeutics and enlists all their major and minor projects
- The report assesses Peripheral Neuropathy (Sensory Neuropathy) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peripheral Neuropathy (Sensory Neuropathy)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • aTyr Pharma, Inc.
  • Baxalta Incorporated
  • CSL Limited
  • GeNeuro SA
  • INSYS Therapeutics, Inc.
  • Neurocentrx Pharma Ltd.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Peripheral Neuropathy (Sensory Neuropathy) Overview

Therapeutics Development

Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Overview

Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis

Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Development by Companies

Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Investigation by Universities/Institutes

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Peripheral Neuropathy (Sensory Neuropathy) - Products under Development by Companies

Peripheral Neuropathy (Sensory Neuropathy) - Products under Investigation by Universities/Institutes

Peripheral Neuropathy (Sensory Neuropathy) - Companies Involved in Therapeutics Development

Araim Pharmaceuticals, Inc.

Arcturus Therapeutics, Inc

aTyr Pharma, Inc.

Baxalta Incorporated

CSL Limited

GeNeuro SA

INSYS Therapeutics, Inc.

Mitsubishi Tanabe Pharma Corporation

Neuren Pharmaceuticals Limited

Neurocentrx Pharma Ltd.

Pfizer Inc.

Polyneuron Pharmaceuticals AG

RegeneRx Biopharmaceuticals, Inc.

Sanofi

Teijin Pharma Limited

Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(immune globulin (human) + hyaluronidase (recombinant)) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

aminoquinol - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cannabidiol - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cibinetide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drugs for Peripheral Neuropathy - Drug Profile

Product Description

Mechanism of Action

R&D Progress

fingolimod hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GL-2045 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GNbAC-1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LUNAR-102 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NNZ-2591 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pirenzepine hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PN-1007 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RGN-352 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SAR-184841 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Synthetic Peptides for Peripheral Neuropathy - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Peripheral Neuropathy (Sensory Neuropathy) - Recent Pipeline Updates

Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects

Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products

Peripheral Neuropathy (Sensory Neuropathy) - Product Development Milestones

Featured News & Press Releases

Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder

Jul 12, 2013: Neuren Receives Notice of Allowance for New Patent

Apr 04, 2013: CSL Behring's Privigen Obtains European Approval For Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy

Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For CSL Behring's Privigen

Jun 27, 2012: PRIMA Study Shows Treatment With Privigen Improved Function In Patients With Chronic Inflammatory Demyelinating Polyneuropathy

May 30, 2012: CSL Behring Submits Marketing Authorization Variation Application To EMA For Privigen In Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Mar 26, 2012: CSL Behring Enrolls First Patient In PATH Trial To Evaluate Hizentra For Treatment Of CIDP

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H1 2016

Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Araim Pharmaceuticals, Inc., H1 2016

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Arcturus Therapeutics, Inc, H1 2016

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by aTyr Pharma, Inc., H1 2016

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Baxalta Incorporated, H1 2016

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by CSL Limited, H1 2016

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by GeNeuro SA, H1 2016

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by INSYS Therapeutics, Inc., H1 2016

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Neuren Pharmaceuticals Limited, H1 2016

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Neurocentrx Pharma Ltd., H1 2016

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Pfizer Inc., H1 2016

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Polyneuron Pharmaceuticals AG, H1 2016

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2016

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Sanofi, H1 2016

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Teijin Pharma Limited, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Recent Pipeline Updates, H1 2016

Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects, H1 2016

Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects (Contd..1), H1 2016

Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H1 2016

Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Top 10 Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Araim Pharmaceuticals, Inc.
Arcturus Therapeutics, Inc
aTyr Pharma, Inc.
Baxalta Incorporated
CSL Limited
GeNeuro SA
INSYS Therapeutics, Inc.
Mitsubishi Tanabe Pharma Corporation
Neuren Pharmaceuticals Limited
Neurocentrx Pharma Ltd.
Pfizer Inc.
Polyneuron Pharmaceuticals AG
RegeneRx Biopharmaceuticals, Inc.
Sanofi
Teijin Pharma Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll